Auxly Cannabis Group (XLY) Planet MicroCap Showcase: TORONTO 2025 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Showcase: TORONTO 2025 summary
23 Oct, 2025Company overview and market position
Operates as a leading Canadian cannabis producer with 6.2% market share and 410 employees.
Back Forty is the top cannabis brand by dollars sold, present in 97% of retail locations.
Focuses on dried flower, pre-rolls, and vapes, which represent 90% of market sales.
Achieved 60% CAGR in top-line growth since 2020.
Generated CAD 139 million net operating revenue and CAD 28 million net income over the last 12 months.
Strategic assets and operational strengths
Leamington facility spans 1.1 million sq ft, with 660,000 sq ft dedicated to cultivation, producing 100,000 kg annually.
85% of output supports own brands, with 15% sold B2B.
Advanced pre-roll production through a five-year R&D partnership, making Back Forty the top non-infused pre-roll brand.
Charlottetown site drives vape innovation, launching first-to-market products and capturing 23% of the all-in-one vape segment.
Consistent focus on quality, cost efficiency, and innovation in core categories.
Financial performance and capital management
Q2 2025 saw record net revenue of CAD 38.8 million, up 33% YoY, with gross margins at 52%.
Achieved CAD 11.6 million adjusted EBITDA and 30% EBITDA margin in Q2.
Generated CAD 8.3 million net income and CAD 4 million cash flow from operations in Q2.
56% EBITDA-to-cash flow conversion rate over the last 12 months.
Recapitalized balance sheet, eliminating CAD 21 million debt and improving working capital to CAD 35 million.
Latest events from Auxly Cannabis Group
- 2025 saw 24% revenue growth, 64% higher Adjusted EBITDA, and strong cash flow conversion.XLY
Q4 202526 Mar 2026 - Delivered 24% revenue growth in 2025 and leads Canadian cannabis with top brands and innovation.XLY
Investor presentation26 Mar 2026 - Q1 2025 saw 29% revenue growth, 48% gross margin, and a return to profitability, but liquidity risks persist.XLY
Q1 202511 Feb 2026 - Record Q2 2025 revenue, profit, and margins, with strong outlook and market leadership.XLY
Q2 202510 Feb 2026 - Net loss narrowed and debt fell, but going concern risk persists amid negative working capital.XLY
Q4 202410 Feb 2026 - Q3 2024 revenue, profit, and market share rose, but liquidity and debt risks persist.XLY
Q3 202410 Feb 2026 - Record Q2 revenue and margin gains, but going concern risks persist.XLY
Q2 202410 Feb 2026 - Record Q3 2025 results and innovation position the company for growth at home and abroad.XLY
Small Cap Growth Virtual Investor Conference 202513 Dec 2025 - Q3 2025 delivered strong revenue and profit growth, with improved margins and reduced debt.XLY
Q3 202513 Nov 2025